EHA 2018 | Developments for the use of MRD in AML
This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted here by Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Dr Hourigan explains the developments in this field, including updated response criteria and the recent publication of a consensus criteria on the measurement of MRD in AML. This video was recorded at the at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
Get great new content delivered to your inboxSign up